Praxis Precision Medicines prices $56.50/share offering, expected $215.6M net proceeds

Praxis Precision Medicines, Inc.

Offering includes 3,318,585 shares at $56.50 and 221,238 pre-funded warrants at $56.4999; underwriters exercised option for 530,973 additional shares.
Net proceeds of ~$215.6M after discounts and expenses; closing expected April 2, 2024.
Proceeds to accelerate PRAX-628 development and continue R&D for ulixacaltamide, PRAX-562, and PRAX-222.
Company believes existing cash plus net proceeds will fund operations into 2027.
Underwriters: Piper Sandler, Guggenheim Securities, and Truist Securities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.